X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.clinicaltrialsarena.com/news/china-cde-innocare-nhl-therapy/
https://www.morphosys.com/en/news/morphosys-share-new-data-pelabresib-and-monjuvir-tafasitamab-cxix-14-presentations-american
https://www.accesswire.com/723752/MorphoSys-to-Share-New-Data-on-Pelabresib-and-MonjuviR-tafasitamab-cxix-in-14-Presentations-at-the-American-Society-of-Hematology-Annual-Meeting
https://www.accesswire.com/721551/MorphoSys-Reports-Preliminary-Q3-2022-Monjuvi-US-Sales-and-Updates-Financial-Guidance-for-2022
https://www.businesswire.com/news/home/20211211005013/en/MorphoSys-and-Incyte-Announce-Additional-Real-World-Evidence-Results-from-RE-MIND2-Study-of-Tafasitamab-Monjuvi%C2%AE-in-Combination-with-Lenalidomide-for-the-Treatment-of-Relapsed-or-Refractory-Diffuse-Large-B-Cell-Lymphoma
https://www.morphosys.com/media-investors/media-center/morphosys-ag-announces-monjuvir-sales-for-the-first-nine-months-and
https://www.prnewswire.com/news-releases/specialised-therapeutics-enters-into-a-new-supply-and-distribution-agreement-with-incyte-to-launch-two-new-cancer-therapies-tafasitamab-and-pemigatinib-in-australia-new-zealand-and-singapore-301406349.html
https://www.ema.europa.eu/en/documents/overview/minjuvi-epar-medicine-overview_en.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761163
https://www.biospace.com/article/releases/incyte-and-morphosys-announce-acceptance-by-health-canada-of-the-new-drug-submission-for-tafasitamab/
https://www.biospace.com/article/releases/xencor-morphosys-and-incyte-enter-into-global-development-collaboration-for-tafasitamab-in-combination-with-plamotamab/
https://www.businesswire.com/news/home/20200818005684/en/National-Comprehensive-Cancer-Network%C2%AE-Adds-Monjuvi%C2%AE-tafasitamab-cxix
https://endpts.com/fda-oks-morphosys-incytes-potential-blockbuster-car-t-alternative/
https://www.fiercepharma.com/marketing/a-first-morphosys-incyte-win-monjuvi-fda-nod-dlbcl-to-challenge-roche-s-polivy
http://www.pmlive.com/pharma_news/ema_starts_review_of_morphosys_tafasitamab_for_lymphoma_1340717
https://finance.yahoo.com/news/morphosys-incyte-announce-antitrust-clearance-213000193.html
https://www.morphosys.com/media-investors/media-center/morphosys-initiates-expanded-access-program-for-tafasitamab-in-the-us-0
https://investor.incyte.com/news-releases/news-release-details/morphosys-and-incyte-sign-global-collaboration-and-license
https://www.reuters.com/article/us-morphosys-trial/morphosys-cfo-says-tafasitamab-drug-sales-potential-above-1-billion-magazine-idUSKBN1Y408H
https://www.reuters.com/article/us-morphosys-trial/morphosys-to-boost-size-of-tafasitamab-drug-trial-on-encouraging-interim-data-idUSKBN1XS21B?feedType=RSS&feedName=healthNews
https://www.reuters.com/article/us-morphosys-trial/morphosys-to-boost-size-of-tafasitamab-drug-trial-on-encouraging-interim-data-idUSKBN1XS21B?feedType=RSS&feedName=healthNews
https://www.reuters.com/article/us-morphosys-trial/morphosys-to-boost-size-of-tafasitamab-drug-trial-on-encouraging-interim-data-idUSKBN1XS21B?feedType=RSS&feedName=healthNews
Market Place
Share 
